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There are common aspects and mechanisms between different types of autoimmune 
diseases such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders 
(NMOSDs), and autoimmune encephalitis (AE) as well as paraneoplastic inflammatory 
disorders of the central nervous system. To our present knowledge, depending on 
the disease, T and B cells as well as antibodies contribute to various aspects of the 
pathogenesis. Possibly the events leading to the breaking of tolerance between the 
different diseases are of great similarity and so far, only partially understood. Beside 
endogenous factors (genetics, genomics, epigenetics, malignancy) also exogenous fac-
tors (vitamin D, sun light exposure, smoking, gut microbiome, viral infections) contribute 
to susceptibility in such diseases. What differs between these disorders are the target 
molecules of the immune attack. For T cells, these target molecules are presented on 
major histocompatibility complex (MHC) molecules as MHC-bound ligands. B cells have 
an important role by amplifying the immune response of T cells by capturing antigen with 
their surface immunoglobulin and presenting it to T cells. Antibodies secreted by plasma 
cells that have differentiated from B  cells are highly structure specific and can have 
important effector functions leading to functional impairment or/and lesion evolvement. 
In MS, the target molecules are mainly myelin- and neuron/axon-derived proteins; in 
NMOSD, mainly aquaporin-4 expressed on astrocytes; and in AE, various proteins that 
are expressed by neurons and axons.
Keywords: T  cell, B  cell, major histocompatibility complex, human leukocyte antigen, multiple sclerosis, 
neuromyelitis optica spectrum disorders, autoimmune encephalitis, paraneoplastic disease
inTRODUCTiOn
Various autoimmune and paraneoplastic disorders of the central nervous system (CNS) share many 
immunological similarities. In these disorders, immunologic tolerance to self-antigens is broken 
(1). This failure can be on the T  cell as well as on the B  cell side or on both sides. The reasons 
why tolerance is broken in autoimmune diseases are multiple and can differ from paraneoplastic 
diseases (2). In autoimmune disease, the initial trigger that leads to breaking of tolerance is not as 
well understood (3). Possibly viral, bacterial and fungal antigens that share antigenic properties 
with self-antigens can result in activation of T or/and B cells that also recognize self-antigens in 
the CNS (4). Another possibility could be that in certain autoimmune-prone individuals compared 
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with non-autoimmune-prone individuals, the T and B cell rep-
ertoires contain higher quantities of cells with a high avidity for 
self-antigens that can be activated and can gain access to the CNS 
in which they find relevant target structures. Such a scenario has 
been underscored in rodent models of CNS autoimmune diseases 
(5). In paraneoplastic diseases of the CNS, epitopes from a neo-
plasm are exposed on antigen-presenting cells to T cells which 
subsequently also recognize an epitope of similar structural 
appearance in the CNS (6).
Importantly, the T and B cell epitopes can differ depending 
on antigen processing in autoimmune disease and possibly also 
paraneoplastic disease (7, 8). In many autoimmune and paraneo-
plastic diseases of the CNS, the B  cell response is much better 
characterized as compared with the T cell response (1, 9). T cell 
help is required for differentiation of B cells into plasma cells and 
affinity maturation of antibodies (10, 11). There are also B cells 
which do not require T cell help in autoimmunity, but these do 
not seem to be of major importance in CNS autoimmunity and 
CNS paraneoplastic diseases as far as one knows to date (12–14).
enDOGenOUS FACTORS
Endogenous factors that contribute to the induction of autoim-
munity or paraneoplastic diseases are multiple. First, genetics is of 
paramount importance. Most autoimmune diseases are complex 
genetic diseases (15). This means that certain allelic variants of 
genes predispose to autoimmunity. There are also few examples of 
autoimmune diseases in which single mutated genes predispose 
to autoimmunity (16). For CNS-directed autoimmune diseases, 
no confirmed single genes with mutations have been discovered 
so far. Much work has been done in elucidating genes that con-
tribute to the complex genetic etiologies (17). Most probably also 
in CNS immune-directed disorders with paraneoplastic origins, 
complex genetics are of importance. RNA expression levels have 
been shown to be altered in autoimmune and paraneoplastic 
diseases of the CNS (18–20). Tissue with altered RNA expression 
levels as compared with healthy tissue might predispose to auto-
immunity and paraneoplastic diseases (21). There is increased 
understanding that epigenetics is very crucial in susceptibility to 
autoimmunity and paraneoplastic disorders (22, 23). Much will 
be learned in the next years regarding epigenetic regulation of 
immunity and autoimmunity.
eXOGenOUS FACTORS
Much has been discovered regarding exogenous factors that affect 
autoimmune diseases of the CNS. These exogenous factors coop-
erate with endogenous factors in susceptibility to autoimmune 
diseases of the CNS (24). Low vitamin D levels as well as low sun 
light exposure have been shown to contribute to susceptibility 
to multiple sclerosis (MS) also independently of other factors 
(25–27). So far, the influence of vitamin D and sun light exposure 
has not been defined to the same degree for neuromyelitis optica 
spectrum disorders (NMOSDs) and autoimmune encephalitis 
(AE) (28). Smoking has a negative influence on MS (29, 30). This 
influence is controlled to some degree by human leukocyte anti-
gen (HLA) genes underscoring that HLA-presented autoantigens 
are possibly modified and promote a more vigorous autoimmune 
response (29). It has been shown that in MS there is a change of 
the gut microbiome (31, 32). Also in NMOSD, changes in the 
gut microbiome have been observed with overrepresentation 
of Clostridium perfringens (33). In experimental autoimmune 
encephalomyelitis (EAE), it has been experimentally proven that 
the gut microbiome contributes to disease susceptibility (34). So 
far, in most types of diseases it is not well defined what specific 
bacteria of the gut microbiome drive autoimmune disease. It has 
been shown that Epstein–Barr virus (EBV) infection has an influ-
ence on MS susceptibility (35, 36). The influence is mainly medi-
ated in childhood and most likely affects the T  cell repertoire. 
Even though a direct role of EBV infection in MS lesion develop-
ment was claimed, this could not be confirmed (37). Also, salt 
intake has been shown to influence EAE susceptibility (38). So far, 
it is not clear if levels of salt intake are influencing susceptibility 
or disease course in MS (39). The elucidation of the influence of 
nutritional factors in various autoimmune diseases of the CNS is 
presently investigated in more detail. Regarding paraneoplastic 
diseases, no such influence has been elucidated so far.
MAJOR HiSTOCOMPATiBiLiTY COMPLeX 
(MHC)/HLA HAPLOTYPeS
Most autoimmune diseases are associated with certain MHC/
HLA haplotypes (40). Such associations also exist for some para-
neoplastic diseases such as paraneoplastic pemphigus (41). So far, 
influences of HLA haplotypes on paraneoplastic diseases have not 
been investigated in much detail. The reason for the haplotype 
preferences of specific autoimmune diseases is not known.
The most likely scenario for influences of HLA haplotypes 
on autoimmune diseases indicates that during early tolerance 
development certain HLA haplotypes select for a T cell repertoire 
that can be self-biased to certain autoantigens and certain organs 
(42–44). In the emergence of tolerance, there is selection of a 
broad range of T cell receptors (TCRs) on various self-antigens. 
In a first step, only T cells are selected that recognize self MHC-
peptide complexes (45–47). In the next step, T cells with TCRs 
with a too high affinity for such complexes are deleted from the 
repertoire (48, 49). MHC displayed peptide repertoires influence 
positive and negative selection (50). Based on the expressed 
HLA haplotypes, the predetermined T cell repertoire differs in 
individuals (51, 52). The TCR repertoire has a bias depending on 
the HLA haplotype in avidity for certain self-antigens (53, 54).
In MHC congenic rat strains, we have shown that there is 
an autoantigen preference that can result, depending on the 
expressed MHC alleles, in disease susceptibility or protection 
from certain diseases (5, 55). Interestingly with increasing com-
plexity of the disease driving autoantigen, the MHC haplotype-
dependent effects alleviate (56, 57). Also, we have shown that the 
amount of autoantigen that leads to disease induction can differ 
between different MHC haplotypes (5, 58). This means that in 
one MHC haplotype minute amounts of antigens are sufficient 
to induce severe disease, while in others much higher amounts 
would be necessary. These findings underscore the influence 
of the antigenic load in context with genetic factors. It has 
been shown that depending on the expressed MHC haplotype, 
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the cytokine preference of the selected T  cell repertoire differs 
(44, 59). Recently in an experimental model of rheumatoid arthri-
tis (RA), it has been shown that MHC alleles that drive disease 
are associated with a T helper cell type 1 (Th1) response with 
secretion of interferon-gamma (IFN-γ) (60). By contrast, protec-
tive MHC alleles promoted an interleukin-17 T helper (Th17) 
cell response. Such a predetermination of cytokine responses 
to disease-inducing factors is potentially also shaped early in 
tolerance development and can also contribute to the finding 
that certain HLA haplotypes predispose to certain autoimmune 
diseases while others protect from disease.
neOAnTiGenS
Tolerance can be broken by presentation of neoantigens on MHC 
molecules to T  cells recognizing antigens that share structural 
similarities to self-molecules (61). Recently, it has been shown 
that neoantigens for presentation on MHC I molecules can be 
generated by fusion of different fragments of degraded proteins 
during antigen processing (62). In addition, endogenous neoanti-
gens could evolve by mutation or translational defects. So far, the 
experimental data that such novel antigens could play a role in the 
induction or maintenance of autoimmune disease of the CNS are 
still lacking but an interesting avenue of future research efforts.
Posttranslational modifications of antigens can also lead to 
induction of autoimmunity (63). This has been shown for RA 
in which citrullinated epitopes have been shown to be disease 
inducing (64, 65). Also for MS, a role for citrullination has been 
proposed but so far there is no proof for the relevance in the 
experimental or human setting (66, 67). Possibly transpeptidation 
could be of importance as has been shown in a model of diabetes 
(68). Changes in glycosylation can affect induction of autoim-
munity (69). Also, other types of posttranslational modifications 
could be of great relevance but have not been investigated in 
much detail regarding CNS autoimmunity or CNS paraneoplastic 
diseases. We have shown that even the conformational state of an 
autoantigen can have different consequences on disease induc-
tion capacity (8). Therefore, different conformations of an antigen 
can be seen be the immune system in a “neoantigenic” fashion 
and lead to autoimmunity (70).
SPeCiFiC DiSeASeS
Multiple Sclerosis
In MS, the target of the autoimmune response, which seems to be 
predominantly T cell driven, is mainly directed against proteins 
of the myelin sheath which is produced by oligodendrocytes (1) 
(Table 1). Myelin basic protein (MBP) is thought to be the major 
autoantigen which is involved (71, 72). Many researchers have 
addressed this topic and found additional myelin proteins that 
can be the target of the autoimmune response (1). There are strong 
indications that the humoral immune response is important as 
well (73). Nevertheless, the exact autoantigens driving this B cell 
response are not known to date in detail. Myelin oligodendrocyte 
glycoprotein (MOG) is a model antigen which has been shown 
to be of major importance driving the B cells response in rodent 
and primate models (74). This protein, which is expressed on 
the outer surface of the myelin sheath, seems to be involved in 
children but not to the same extent in older people with MS in 
the immune pathogenesis of MS (75). Especially young children 
with MS with an age under 10  years have a robust anti-MOG 
antibody response. This finding underscores that potentially early 
in life immunological events are taking place that predispose to 
development of MS later in life. CNS lesions of MS patients show 
antibody-dependent complement destruction underscoring the 
importance of the antibody response in MS (73). Moreover, pro-
teins expressed on neurons and axons have also been discussed 
to be targets of the immune response in patients with MS based 
on work in EAE (76). Recently, in patients with MS, we have 
shown that peptides can be eluted from MHC molecules from 
CNS tissue that are recognized by T cells secreting IFN-γ (Th1) 
(72, 77). Importantly, the increased immune reactivity against 
such peptides is observed in patients with active MS, i.e., in patients 
with MS who have an acute bout- or/and contrast-enhancing 
lesions in the CNS indicating active inflammation. This finding 
underscores that the adaptive immune response against CNS-
derived autoantigens is of significance in MS. Importantly, the 
T cell reactivity is directed not only against MBP but additional 
autoantigens and differs between individuals.
neuromyelitis Optica Spectrum Disorders
In NMOSD, it has been demonstrated that the immune response 
is targeting aquaporin-4 (AQP4), a water channel protein on 
astrocytes (127) (Table 1). Certain cases of NMOSD are associ-
ated with an immune response against MOG (128). In both types, 
antibody-dependent tissue destruction is of major importance 
(96). The role of T cells is presently analyzed in more detail (94). 
In rodent models, it has been delineated that direct injection of 
anti-AQP4 antibody in the CNS can lead to severe pathology 
without the presence of T cells (129). Also, antibody-dependent 
destruction of tissue by complement seems to be of paramount 
importance and dependent on the antigen conformation and the 
presence of antibodies (130). It is not excluded that also addi-
tional target molecules will be discovered, which are associated 
with seronegative forms of NMOSD in the future.
Autoimmune encephalitis
There are a high number of diseases in which the autoimmune 
response is directed against neuronal antigens (1) (Table 1). The 
target molecules can be localized intracellular or extracellular 
(9, 98). Some of the intracellular antigens are nuclear proteins. 
Most of the diseases in which the immune response is directed 
against intracellular neuronal targets are of paraneoplastic 
origin. Mainly, CD8+ T cells, which are MHC I restricted, are 
involved in the immune pathogenesis of these types of AE (131). 
In affected patients, most important is the search for the underly-
ing neoplasm and its treatment. In addition, immunotherapy is 
meaningful (132).
In diseases in which the target structures are exposed extracel-
lular as membrane proteins, more diseases are of autoimmune 
origin and less paraneoplastic. A prototype is the anti-N-methyl-
d-aspartate receptor (NMDA) receptor encephalitis in which the 
NMDA receptor is the target molecule of the immune response 
TABLe 1 | Human diseases and autoantigens, main cellular expression, and cellular compartment of expression as well as involved immune responses 
as presently known.
Disease (Auto)antigen Target cell Main cellular localization established role of
T cells Antibodies Complement
MS Actin U C, CS, ES + (72) ND ND
MS Alpha-synuclein N U, not P + (72) ND ND
MS CNPase, 2′,3′-cyclic-nucleotide 3′-phosphodiesterase O, N ES, CS, N + (78) + (79) ND
MS GFAP, glial fibrillary acidic protein A C, CS + (72) − (80) ND
MS Glutamate dehydrogenase U M + (72) ND ND
MS MAG, myelin-associated glycoprotein O PM + (81) + (81) ND
MS MBP, myelin basic protein O PM, C, N + (72, 82, 83) + (79) ND
MS MOBP, myelin-associated oligodendrocyte basic protein O PM + (84) + (79) ND
MS MOG, myelin oligodendrocyte glycoprotein O PM + (85, 86) + (87) + (88)
MS Neurofilament-3 N CS, C, N + (72) + (89) ND
MS PLP, proteolipid protein O PM + (90) + (79) ND
MS S100β, S100 calcium-binding protein B A E, C, N + (91) − (80) ND
MS Survivin U C, CS, N + (72) ND ND
MS Transaldolase U E, C, N + (92) + (93) ND
NMOSD AQP4, aquaporin-4 A PM + (94) + (95) + (96)
NMOSD MOG, myelin oligodendrocyte glycoprotein O PM ND + (97) + (88)
AE AK5, adenylate kinase 5 N C, ES ND + (98) ND
AE AMPAR, glutamate ionotropic receptor AMPA type N PM ND + (99) ND
AE Amphiphysin N PM, C, CS, GA ND + (100) ND
AE CASPR2, contactin associated protein-like 2 N PM, E, GA ND + (101) ND
AE CRMP5, dihydropyrimidinase-like 5 N C ND + (102) ND
AE DNER (Tr), delta-/notch-like EGF repeat containing N PM, E ND + (103) ND
AE Dopamine receptor D2 N PM, C ND + (104) ND
AE DPPX, dipeptidyl peptidase N ES, L, PM, V ND + (105) ND
AE GABAaR, gamma-aminobutyric acid type A receptor N PM ND + (106) ND
AE GABAbR, gamma-aminobutyric acid type B receptor N PM ND + (107) ND
AE GAD65, glutamate decarboxylase 2 N C, PM + (108) + (109) − (108)
AE GlyR, glycine receptor N PM ND + (110) ND
AE Hu, ELAV-like RNA-binding protein 4 N C, N + (108, 111) + (112) − (108)
AE IgLON5, IgLON family member 5 N ES, PM ND + (113) ND
AE LGI1, leucine-rich glioma-inactivated 1 N ES, PM + (108) + (114, 115) + (108)
AE Ma1, paraneoplastic Ma antigen 1 N N ND + (116) ND
AE Ma2, paraneoplastic Ma antigen 2 N N + (108) + (117) − (108)
AE mGluR1, glutamate metabotropic receptor 1 N PM, C ND + (118) ND
AE mGluR5, glutamate metabotropic receptor 5 N ES, PM ND + (119) ND
AE Neurexin-3a N PM ND + (120) ND
AE NMDAR, glutamate ionotropic receptor NMDA type N PM + (108) + (121) − (108)
AE P/Q type VGCC, calcium voltage-gated channel N PM ND + (122) ND
AE Ri, NOVA alternative splicing regulator 1 N N ND + (123) ND
AE Yo, cerebellar degeneration-related protein 2 N N ND + (124, 125) ND
AE Zic4, Zic family member 4 N N ND + (126) ND
A, astrocytes; AE, autoimmune encephalitis; C, cytosol; CS, cytoskeleton; E, endosome; ES, extracellular space; GA, Golgi apparatus; L, lysosome; M, mitochondria; MS, multiple 
sclerosis; N, neurons; N, nucleus; ND, not determined; NMOSD, neuromyelitis optica spectrum disorder; O, oligodendrocytes; P, peroxisome; PM, plasma membrane; U, ubiquitous; 
V, vacuoles; +, positive findings; −, negative findings.
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(121). It has been shown that antibodies are most important in 
this type of diseases and that these antibodies can lead to altera-
tion of cellular function with consequences on behavior (104, 
133, 134) or tissue destruction by complement (108). There is a 
requirement for these antibodies to access the CNS in order to 
be of disease relevance (135). Recently, a strong influence of a 
specific HLA haplotype has been shown in anti-LGI1 encephalitis 
in Koreans (136). So far, the role of T cells has not been assessed 
in detail in these illnesses but deserves much more attention 
in future efforts. These diseases are treated by immunotherapy 
(132, 137). In cases in which the origin is paraneoplastic, the 
neoplasm needs to be treated in addition to immunotherapy.
Paraneoplastic Disease of the CnS
Why is there such a preference of paraneoplastic CNS disorders 
for neuronal antigens? Why are there no or only few cases of 
paraneoplastic MS or NMOSD? Possibly the answer lies in 
the antigen repertoires that are preferentially displayed by 
neoplasms. In NMOSD, cases with paraneoplastic origin have 
been reported (138, 139). In addition, certain brain neoplasms 
might result in paraneoplastic cases of MS even though such 
cases have not been interpreted as paraneoplastic diseases so far 
but rather in the opposite way that the molecular changes in the 
MS lesion have led to development of the neoplasms (140–142). 
As discussed in the section regarding HLA haplotypes, the 
FiGURe 1 | Schematic representation of the major histocompatibility 
complex (MHC)/human leukocyte antigen (HLA) haplotype and 
additional factors on disease breakthrough in autoimmune or/and 
paraneoplastic diseases.
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density of the presented disease-inducing antigen expressed by 
the neoplasms is potentially an important factor that can lead 
to paraneoplastic disease. Therefore, a higher density of the 
presented autoantigen would possibly more likely lead to disease 
induction.
THeRAPeUTiC COnSiDeRATiOnS
Since the adaptive immune response is of such great relevance 
in various immunologically mediated disorder of the CNS it is 
obvious that it should be targeted to halt and possibly cure auto-
immune and paraneoplastic diseases of the CNS. Of course, in 
paraneoplastic diseases always the underlying malignancy should 
be treated by surgical, radiotherapeutic, and chemotherapeutic 
approaches, since the eradication of the malignancy with pres-
ence of the antigens that drive the disease can possibly lead to an 
improvement of the paraneoplastic disease condition affecting the 
CNS. It has been proposed that immunotherapeutic approaches 
should mainly affect the humoral immune response, since the 
cellular immune response by CD8+ T cells is of great importance 
in tumor rejection (143). This aspect needs to be investigated in 
more depth.
In autoimmune diseases of CNS depending on the dominance 
of the T or/and B  cell response, a rational treatment approach 
should be used. In most diseases in which autoantibodies are of 
major importance, the depletion of B cells by rituximab a mono-
clonal antibody (mAb) that targets CD20 has been shown to be of 
great efficacy (144–146). This is the case for AE with membrane 
molecules as target antigens of the immune response (132, 137, 
146). In NMOSD, depletion of B cells is well established as a very 
efficacious treatment approach (145). Also in MS, depletion of 
B cells has been shown to be of great therapeutic efficacy (144). 
This has been underscored by recent data with ocrelizumab a 
novel human mAb also targeting CD20 (147, 148). Since B cells 
are very potent professional antigen-presenting cells, the deple-
tion of such cells leads also to reduced presentation of antigens 
to T cells (1, 149, 150). This reduction of antigen presentation in 
individuals that have been treated with B cell depleting agents is 
potentially one of the most important immunotherapeutic effects 
of such a therapeutic approach.
In MS, it has been demonstrated that decreasing numbers 
of T cells that enter the CNS can result in reduction of contrast 
enhancing lesions, numbers of new lesions, and improvement of 
clinical disease score as well (3). Also, modulating T cell responses 
regarding the way how these cells react in expression of certain 
immune mediators can affect disease.
The combined depletion of T and B  cells by alemtuzumab 
by targeting CD52 has been shown to be very efficacious in 
MS (151–153). In a retrospective case series in NMOSD, this 
approach failed to be effective (154). The reasons are not clear so 
far, but the authors recommend caution. The approach has not 
been used in AE so far. This restricted use is most likely because 
potential side effects are dreaded. Nevertheless, such a therapeutic 
approach embodies a great potential for cure in selected patient 
populations.
Another approach to affect autoimmune and paraneoplastic 
diseases would be the blockade of the terminal phase of inflam-
mation which is partially mediated by antibodies and that leads 
to tissue destruction. In this aspect, the use of eculizumab, a 
mAb depleting the complement factor C5 holds great promise. 
There are trials ongoing in NMOSD that investigate the efficacy 
of eculizumab in disease arrest. Initial observations are very 
promising (155). The use of complement inhibitors could be of 
great therapeutic potential in MS as well as in certain types of AE 
in which complement is strongly involved in pathophysiology. 
So far, the use of eculizumab is restricted due to limited clinical 
development efforts because of its high cost.
COnCLUSiOn
There is a great similarity in immune mechanisms of different 
autoimmune and paraneoplastic diseases of the CNS (Figure 1). 
The adaptive immunity seems to be the main driver of selected 
organ pathology in autoimmune and paraneoplastic diseases. 
Specific HLA haplotypes are associated with different autoim-
mune and paraneoplastic autoimmune disorders. HLA haplo-
types predispose for selection of certain autoantigens that drive 
such diseases. The phenotype of autoimmune and paraneoplastic 
diseases of the CNS differs depending on the antigens that drive 
the immune responses. Neoantigens can possibly contribute to 
the development of these disorders. The pivotal role of the adap-
tive immunity in autoimmune and paraneoplastic diseases of the 
CNS allows directed immune interventions to modulate T and 
B cell responses.
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